ASMB

Assembly Biosciences Inc

Stock NASDAQ – Stock Market Prices, News & Analysis

Assembly Biosciences Inc is a biotechnology company focused on developing treatments for infectious diseases such as hepatitis B and microbiome disorders.

$ 28.23
1.67 %

Assembly Biosciences Inc

$ 28.23
1.67 %
ASMB

Assembly Biosciences Inc is a biotechnology company focused on developing treatments for infectious diseases such as hepatitis B and microbiome disorders.

Price history of Assembly Biosciences Inc
Price history of Assembly Biosciences Inc

Performance & Momentum

6 Months 2.65 %
1 Year 171.18 %
3 Years 137.63 %
5 Years 45.29 %

Strategic Analysis

Assembly Biosciences Inc • 2026

Assembly Biosciences Inc positions itself as an innovative player in the biotechnology sector, focused on developing advanced treatments for infectious diseases, particularly hepatitis B and microbiome-related conditions. Its therapeutic specialization and targeted approach to unmet medical needs give it a promising niche in healthcare.

Strengths
  • Deep expertise in innovative antiviral treatments
  • Positioned in a high-potential medical growth segment
  • Favorable stock performance over the past year, supporting the validation of its pipeline
Weaknesses
  • History of volatility in the medium and long term
  • Lack of recent major catalysts in public communication
Momentum

Current momentum indicates positive dynamics supported by a resurgence of interest from investors, reflecting confidence in the evolution of the therapeutic pipeline. Although the biotechnology context remains subject to some volatility, the trend is encouraging for a cautious positioning geared toward the medium term.

Similar stocks to Assembly Biosciences Inc

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone